FDA grants priority review to Roche’s Tecentriq monotherapy as first-line treatment of certain people with advanced non-small cell lung cancer


You May Also Like

Corvus Pharmaceuticals Reports Third Quarter 2017 Financial Results and Clinical Program Update

BURLINGAME, Calif., Nov. 02, 2017 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage ...

Pulse Biosciences Announces Closing of Initial Public Offering Over-allotment

BURLINGAME, Calif., June 21, 2016 (GLOBE NEWSWIRE) -- Pulse Biosciences, Inc. (Nasdaq:PLSE), today announced ...